BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

InterMed Discovery Receives Michael J. Fox Foundation Award for IMD-026259


1/20/2010 1:34:52 PM

Dortmund, Germany, January 20, 2010 – InterMed Discovery (IMD), a world class natural product lead-discovery company, today announced that it has received an award from The Michael J. Fox Foundation for Parkinson’s Research for its programme to develop IMD-026259 as a pharmaceutical treatment to challenge neuro-degeneration in Parkinson’s disease (PD).

PD is a disease of progressive neuro-degeneration where the cells of particular brain regions involved in the production of dopamine die progressively in a process involving “oxidative stress”. The oxidative stress seen in PD is caused by dysfunctional mitochondria activating the downstream signal protein HIF-1. Therefore negative regulation of the HIF-1 signal is thought to be a valid therapeutic strategy towards reduction of neurotoxicity mediated by oxidative stress and subsequent neuro-inflammation. IMD’s naturally based product candidate IMD-026259 inhibits HIF-1 and has already demonstrated potent neuro-protective capabilities in several biological models including PD.

“Due to its innovative point of intervention, we consider IMD-026259 to be a novel disease-modifying therapeutic approach to oxidative stress related, neuro-inflammatory diseases such as PD,” said Philipp Wabnitz, Head Pharmacology at InterMed Discovery.

“These funds will enable us to further substantiate preclinical proof of principle towards development of this promising product candidate,“ said Dr. Thomas Henkel, co-Managing Director of InterMed Discovery.

“The award is also a validation of the quality and our previous investments in this project,” added Bernard Becker, co-Managing Director of InterMed Discovery.

About InterMed Discovery

InterMed Discovery is an emerging world class natural product lead-discovery company, driving innovation through the generation of novel product candidates for the life science, food and cosmetics industries. Using one of the most powerful validated natural product discovery engines, InterMed Discovery generates proprietary product pipelines of early stage pharmaceuticals and functional ingredients and also supports partners in research and lead generation. Biologically characterised product leads are identified using IMD BIOPROFILING® and NPSilico®, which together comprise a proprietary bioinformatics platform drawing on screening results compiled over many years, complemented by primary biological and chemical research on natural products. InterMed Discovery adds to this the industry’s largest collections of pure compounds, sample fractions and mixtures as its source for potential natural product leads. The Company is located in Dortmund, Germany and was founded in 2006 as a management buyout of the Natural Products Research Unit of Bayer Healthcare. IMD entered into strategic cooperations with companies such as Cognis GmbH and Biotropics Malaysia Berhad. Further information on InterMed Discovery can be found at www.intermed-discovery.com

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson’s disease through an aggressively funded research agenda. MJFF has funded nearly $170 million in research to date. For more information please visit www.michaeljfox.org

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->